What can be done about PCOS hair growth and hair loss?
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Short answer
Unwanted hair growth and scalp thinning in PCOS are treated on a six month timescale, because that is the hair cycle. The combined oral contraceptive pill is first line, with laser or electrolysis alongside. Spironolactone is added if the response is inadequate after at least six months, and it requires effective contraception because it can undervirilise a male fetus.
Hirsutism and female pattern hair loss in PCOS are both androgen-driven, and both respond slowly. The 2023 International Evidence-based Guideline puts the combined oral contraceptive pill first for hirsutism, adds mechanical laser and light therapies, and reserves anti-androgens for an inadequate response after at least six months of the pill or cosmetic therapy. Nothing here works in weeks. A terminal hair follicle takes months to cycle out.
The first six months
The pill lowers ovarian androgen output and raises sex hormone binding globulin, so free testosterone falls. Existing hairs still have to grow out. The Endocrine Society hirsutism guideline suggests oral contraceptives as initial therapy for most women not seeking fertility, and suggests adding an anti-androgen only after six months of pill monotherapy without adequate improvement. Judging the pill at eight weeks is the commonest reason women conclude it failed.
Spironolactone, and why contraception is mandatory
Spironolactone blocks the androgen receptor and is the anti-androgen most used in the United States. The 2023 PCOS guideline positions anti-androgens "in combination with effective contraception" and requires counselling about "the risks of incomplete development of external genital structures of male fetuses (undervirilisation)". The FDA label for spironolactone states the drug "may affect sex differentiation of the male during embryogenesis" and advises avoiding it in pregnancy. The Endocrine Society guideline suggests against anti-androgen monotherapy unless adequate contraception is used.
Hair removal and scalp thinning
Mechanical laser and light therapy should be considered for facial hirsutism in PCOS, and the guideline notes benefits for related depression, anxiety and quality of life. The Endocrine Society suggests photoepilation for auburn, brown or black hair and electrolysis for white or blonde hair, since laser targets pigment. Scalp hair loss in PCOS is female pattern hair loss and is treated separately, usually with topical minoxidil, with anti-androgens as an adjunct. Scalp regrowth is slower and less complete than facial hair reduction.
| Treatment | Time to judge | Requirement |
|---|---|---|
| Combined oral contraceptive pill | 6 months | No oestrogen contraindication |
| Laser or light therapy | Several sessions over months | Pigmented hair |
| Electrolysis | Months, per follicle | Works on white or blonde hair |
| Spironolactone | 6 months | Effective contraception, potassium check if risk factors |
| Topical eflornithine | 8 weeks for slowing | Facial use, continuous |
Set the review date when you start, not when you are frustrated. Take a photograph at baseline in the same light. If there has been no change at six months on a pill plus cosmetic therapy, that is the point at which adding spironolactone is a guideline-supported step, with contraception in place.
The clinical detail
Spironolactone dosing: the 2023 PCOS guideline notes that 25 to 100 mg per day "appears to have lower risks of adverse effects", while dermatology and endocrinology practice in the United States commonly uses 50 to 200 mg daily for hirsutism and acne. Cyproterone acetate at doses of 10 mg or more is not advised because of meningioma risk. Flutamide is not recommended by the Endocrine Society because of hepatotoxicity.
Potassium monitoring: a study of 974 healthy young women taking spironolactone for acne found hyperkalaemia in 0.72 per cent against a 0.76 per cent baseline rate in the general population, and repeat testing of the elevated values was normal in all six retested. Routine potassium monitoring in otherwise healthy young women is therefore low yield, though it remains appropriate with renal impairment, ACE inhibitors, potassium supplements or older age.
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Sources
- International Evidence-based Guideline for the Assessment and Management of PCOS, 2023 summary. Monash University Centre for Health Research and Implementation
- Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. Endocrine Society. PMID 29522147
- ALDACTONE (spironolactone) prescribing information. US Food and Drug Administration
- Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne. JAMA Dermatology. PMID 25796182
This library is educational and is not individual medical advice. Read our Editorial and Medical Review Policy.